The Sequencing Challenge — With T-DXd proving successful in both the neoadjuvant and adjuvant settings, where does this drug belong? Drs. Pegram and Iyengar unpack the major “dual success” of the DESTINY-Breast11 and DESTINY-Breast05 trials and debate the optimal strategy for HER2+ patient care.
Deciphering the T-DXd Dilemma: Dual Success in DESTINY-Breast11 and DESTINY-Breast05
You may also like
Recommended Videos
